Abstract
Rosacea, a chronic, inflammatory skin condition, is estimated to affect ten million Americans [1]. Characterized by a centrofacial distribution of acneiform papules and pustules, diffuse erythema, and frequently but not always telangiectases [2], rosacea is a highly visible disease that has been associated with negative influences on affected individuals’ quality of life [3, 4]. Although the disease is generally thought to be of primarily cosmetic consequence, patients have reported stinging and pain associated with rosacea [5], and functional impairments may result from severe rhinophyma [6]. A number of treatment options are available—both topical and systemic—for the management of rosacea in its various presentations. With a proper diagnosis, a rational therapeutic strategy, and supportive skin care and patient education, control of rosacea is possible.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55:77–81.
Diamantis S, Waldorf HA. Rosacea: clinical presentation and pathophysiology. J Drugs Dermatol. 2006;5:8–12.
Balkrishnan R, McMichael AJ, Hu JY, Camacho FT, Shew KR, Bouloc A, et al. Correlates of health-related quality of life in women with severe facial blemishes. Int J Dermatol. 2006;45:111–5.
Aksoy B, Altaykan-Hapa A, Egemen D, Karagöz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163:719–25.
Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907–12.
Hoasjoe DK, Stucker FJ. Rhinophyma: review of pathophysiology and treatment. J Otolaryngol. 1995;24:51–6.
Wollina U. Rosacea and rhinophyma in the elderly. Clin Dermatol. 2011;29:61–8.
Feldman SR, Hollar CB, Gupta AK, Fleischer Jr AB. Women commonly seek care for rosacea: dermatologists frequently provide the care. Cutis. 2001;68:156–60.
Elsaie ML, Choudhary S. Updates on the pathophysiology and management of acne rosacea. Postgrad Med. 2009;121:178–86.
Elewski BE, Draelos Z, Dréno B, Jansen T, Layton A, Picardo M. Rosacea-global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011;25:188–200.
Jones DA. Rosacea, reactive oxygen species, and azelaic acid. J Clin Aesthet Dermatol. 2009;2:26–30.
Marks R. The enigma of rosacea. J Dermatolog Treat. 2007;18(6):326–8.
McAleer MA, Fitzpatrick P, Powell FC. Papulopustular rosacea: prevalence and relationship to photodamage. J Am Acad Dermatol. 2010;63:33–9.
National Rosacea Society website. http://www.rosacea.org/patients/materials/tripwires.php. Accessed 21 Sept 2011.
Oltz M, Check J. Rosacea and its ocular manifestations. Optometry. 2011;82:92–103.
Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea. 2003;22:230–3.
Lipozencic J, Ljubojevic S. Perioral dermatitis. Clin Dermatol. 2011;29:157–61.
Ljubojeviae S, Basta-Juzbasiae A, Lipozenèiae J. Steroid dermatitis resembling rosacea: aetiopathogenesis and treatment. J Eur Acad Dermatol Venereol. 2002;16:121–6.
Zhao YE, Wu LP, Peng Y, Cheng H. Retrospective analysis of the association between Demodex infestation and rosacea. Arch Dermatol. 2010;146:896–902.
Bikowski JB, Del Rosso JQ. Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton. J Clin Aesthet Dermatol. 2009;2:20–5.
Draelos ZD. Treating beyond the histology of rosacea. Cutis. 2004;74(3 Suppl):28–31. 32–34.
Bikowski J. The use of therapeutic moisturizers in various dermatologic disorders. Cutis. 2001;68(5 Suppl):3–11.
Conde JF, Yelverton CB, Balkrishnan R, Fleischer Jr AB, Feldman SR. Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol. 2007;6:495–8.
Del Rosso JQ, Baum EW, Draelos ZD, et al. Azelaic acid gel 15%: clinical versatility in the treatment of rosacea. Cutis. 2006;78(5 Suppl):6–19.
Del Rosso JQ, Bhatia N. Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application. Cutis. 2011;88:67–72.
van Zuuren EJ, Kramer S, Carter B, Graber MA, Fedorowicz Z. Interventions for rosacea. Cochrane Database Syst Rev. 2011;16:CD003262.
Bikowski JB. The pharmacologic therapy of rosacea: a paradigm shift in progress. Cutis. 2005;75(3):27–32.
Wolf Jr JE. Present and future rosacea therapy. Cutis. 2005;75(3 Suppl):4–7.
Kennedy Carney C, Cantrell W, Elewski BE. Rosacea: a review of current topical, systemic and light-based therapies. G Ital Dermatol Venereol. 2009;144:673–88.
Jansen T, Plewig G. Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities. Facial Plast Surg. 1998;14:241–53.
Park H, Del Rosso JQ. Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol. 2011;4:54–61.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bikowski, J. (2014). Rosacea. In: Zeichner, J. (eds) Acneiform Eruptions in Dermatology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8344-1_43
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8344-1_43
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8343-4
Online ISBN: 978-1-4614-8344-1
eBook Packages: MedicineMedicine (R0)